Phase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients

Background null SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN]) is a relatively non-toxic, targeted therapy based on the Warburg Effect. It may be well suited for pancreas cancer because of its ability to penetrate tumors and tolerability in compromised patients. null null null Methods null Subjects progressed on at least one line of chemotherapy were randomized to receive either 460 mg/d or 920 mg/d single agent SM-88 administered with low...